Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravenous midazolam versus diazepam for non-convulsive status epilepticus with unknown symptom onset
ChiCTR1900027967Phase 4Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Guangxi Medical University
- Start
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in status epilepticus (SE) comparing Midazolam Group with Diazepam Group (2 arms). Primary endpoints: Recurrence rate of non-convulsive status epilepticus within 14 days and Change from baseline in mean daily Glasgow score during days 1 to 14. Planned start Jan 2020; status: not yet recruiting.
02
Drugs
midazolamdiazepam
03
Conditions
status epilepticus (SE)
Beyond the preview
Go deeper on ChiCTR1900027967.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900027967.